ReviewHeart failure reviews2025
Special topics: heart failure-related cardiogenic shock, valvular heart disease and end-stage renal disease. Part 4 of the International Expert Opinion Series on Acute Heart Failure Management.
Review in Heart failure reviews, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute heart failure (AHF) remains a major global health challenge, contributing significantly to morbidity, mortality, and healthcare resource utilization. Among its clinical phenotypes, heart failure-related cardiogenic shock (HF-CS) represents a particularly severe and complex presentation that differs from acute myocardial infarction-related cardiogenic shock in terms of clinical characteristics, haemodynamic profiles, therapeutic response, and outcomes. In a subset of patients, AHF is related to or coexists with valvular heart diseases (VHDs) that require specific management strategies and treatments, namely aortic stenosis, mitral stenosis, aortic regurgitation, and mitral regurgitation. Another challenging scenario is represented by AHF in patients with end-stage renal disease (ESRD), since the risk of adverse outcomes is particularly high, conventional diuretic strategies cannot be pursued, and renal replacement therapy is frequently required. In this state-of-the-art review (part 4 of the International Expert Opinion Series on AHF Management), we propose a pragmatic, evidence-based framework for managing AHF complicated by HF-CS, VHDs, or ESRD.
Indexed as
Identifiers
41102558What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.